【摘 要】
：
Glioma is a malignant primary tumor with the highest intracranial incidence.It is also among the top three cancers,which are of the highest mortality,including pancreatic cancer and lung cancer.At pre
【出 处】
：
中国微米纳米技术学会纳米科学技术分会第四届年会暨2016国际纳米生物与医学学术会议
论文部分内容阅读
Glioma is a malignant primary tumor with the highest intracranial incidence.It is also among the top three cancers,which are of the highest mortality,including pancreatic cancer and lung cancer.At present,the most common clinical treatment for glioma is surgical resection.However,because of its inherent invasive growth and the "leek-like" proliferation,only surgical excision cannot achieve a thorouph biological removal of glioma.But instead,it will speed up the malignant proliferation.On the other hand,since lesions occur in brain,the existence of blood-brain-barrier(BBB)provides sufficient protection for subclinical glioma cells.Due to the abundant blood flow and nutrient supply in brain,proliferation cycle of glioma can be only less than a week.Therefore,the chance of recurrence greatly increases.And adjuvant treatments with genetic or chemical drugs seem to be indispensable.While the existence of BBB largely limits the effective accumulation of genetic or chemical drugs in glioma tumor site.Therapeutic drugs rapidly distribute to other organs with circulation,inducing unwanted systemic adverse reactions.In consequence,developing glioma-targeting and glioma-responsive releasing drug delivery systems has been one of the important difficulties in field of glioma therapy.
其他文献
Gastric cancer is the second leading cause of cancer-related death worldwide.RNA nanotechnology has recently emerged as an important field due to recent findings of its high thermodynamic stability,fa
Beside cellular up-taking,the extremely low-efficient cytosolic release of the internalized siRNA has been concerned for intracellular siRNA delivery[1],and the early endosomal release was certificate
CD44 is a well-established cell surface receptor that has been successfully used to design tumor targeting nanocarriers for cancer treatment.However,normal cells such as mesenchymal stem cells and fib
In recent years,developing bioinspired delivery systems has attracted wide attentions in the field of biomedical nanomaterials for cancer therapy.With the rational molecular and supramolecular enginee
Nutrient transporters have been explored for biomimetic delivery targeting the brain.The albumin-binding proteins(e.g.,SPARC and gp60)are overexpressed in many tumors for transport of albumin as an am
Some gases such as CO,NO and H2S have remarkably therapeutic activity,especially to two most important diseases,cancer and cardiovascular disease.[1] However,their uncontrollable administration can br
Over past three decades,the approaches to targeting nanomaterials in vivo have been intensely explored.However,the level of antitumor agent in tumor sites is still low.Thus,the development of new drug
In vivo application of drug delivery systems faces inevitable challenges of numerous physiological barriers.Overcoming of these barriers often requires very different,or even contradictory properties
Therapeutic biomacromolecules such as proteins and peptides have been gaining increased popularity to treat various diseases since 1970s(1).This significantly increases the demand of simple routes of